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The field of pharmacogenomics has made great strides in oncology over the last
20 years and indeed a significant number of pre-emptive genetic tests are now rou-
tinely undertaken prior to anticancer drug administration. Many of these gene–drug
interactions are the fruits of candidate gene and genome-wide association studies,
which have largely focused on common genetic variants (allele frequency>1%). Exam-
ples where there is clinical utility include genotyping or phenotyping for G6PD to pre-
vent rasburicase-induced RBC haemolysis, and TPMT to prevent thiopurine-induced
bone marrow suppression. Other associations such as CYP2D6 status in determining
the efficacy of tamoxifen are more controversial because of contradictory evidence
from different sources, which has led to variability in the implementation of testing.
As genomic technology becomes ever cheaper and more accessible, we must look to
the additional data our genome can provide to explain interindividual variability in
anticancer drug response. Clearly genes do not act on their own and it is therefore
important to investigate genetic factors in conjunction with clinical factors, inter-
acting concomitant drug therapies and other factors such as the microbiome, which
can all affect drug disposition. Taking account of all of these factors, in conjunction
with the somatic genome, is more likely to provide better predictive accuracy in
determining anticancer drug response, both efficacy and safety.
This review summarises the existing knowledge related to the pharmacogenomics of
anticancer drugs and discusses areas of opportunity for further advances in per-
sonalisation of therapy in order to improve both drug safety and efficacy.
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1 | INTRODUCTION
The fundamental aspects of pharmacogenomics can be traced back to
510BCE and the observations of Pythagoras who noted that some
individuals became ill after eating fava beans (favism). We now know
this intolerance of fava bean is due to glucose-6-phosphate dehydro-
genase (G6PD) deficiency1 caused by deleterious variants in the gene
encoding the enzyme. Coincidentally, G6PD deficiency is now known
to be important in oncology as it is associated with an increased risk
of haemolysis in patients administered rasburicase for prevention of
tumour lysis syndrome.2
Oncology is considered to be the field of medicine in which
pharmacogenomics and personalised medicine is perhaps most
established. Indeed, oncology indications represent 140/362 (39%) of
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all Food and Drug Administration drug label warnings related to
pharmacogenomic markers3 (accessed 1August 2019). However, only
24 of these (20%) relate to germline, nontumour variants associated
with interindividual variability in response (either safety or efficacy).
Furthermore, just 21 of these drug label warnings report/describe an
actual association (Table 1).
Several different approaches to the identification of predictive
genetic biomarkers have been utilised in the previous 2 decades. Ini-
tially candidate genes studies analysing associations with variants in
genes with a priori knowledge of impact on drug pharmacokinetics
and pharmacodynamics were undertaken. However, as our under-
standing on population genetics, linkage disequilibrium (LD) and hap-
lotype structure developed, genome-wide associations studies
allowed us to conduct unbiased studies and thus identify novel loci
associated with drug response. This understanding of the complexities
of population LD has given us an understanding of differences in LD
and allele frequencies in different ethnicities, evidenced by differ-
ences in drug responses between different ethnic groups.36 It is
important to note, however, that much of this work is based on asso-
ciations with genetic variants that are common, often with a minor
allele frequency >5%. Looking forward, as next-generation sequencing
(NGS) becomes more routinely embedded within research studies,
and eventually into clinical practice, the role of low penetrance, low
frequency and even personal variants, will need to be evaluated in
drug response, which will only be possible with large-scale population
studies linked to electronic health record databases.
There are some important examples of oncology drugs where the
level of evidence for gene–drug interactions is substantial and clinical
validity/utility of pre-emptive testing is demonstrable to the extent
that it is recommended or, in some instances, mandated. In this
review, we provide an up-to-date analysis of gene–drug interactions
in the field of oncology focusing on germline variants, rather than
somatic variants. There are number of oncology drugs where genetic
variation in genes encoding drug metabolising enzymes are associated
with interindividual variability in outcome for efficacy and/or safety
(Figure 1).
2 | ASSOCIATIONS WITH A HIGH LEVEL OF
EVIDENCE
2.1 | TPMT/NUDT15 and thiopurines
6-Mercaptopurine is used in the treatment of acute lymphoblastic
leukaemia (ALL). It is metabolised by thiopurine methyltransferase
(TPMT) to an inactive methylmercapturine resulting in less parent
drug available for the formation of pharmacologically active, and
potentially toxic, thioguanine nucleotide (TGN) metabolites. Variant
alleles of TPMT are associated with low enzyme activity and conse-
quently increased TGN levels leading to pronounced pharmacological
effects. Indeed, individuals who inherit 2 loss-of-function alleles are at
significantly increased risk of life-threatening myelosuppression as a
result of increased TGN exposure.
Estimates suggest that between 5.8 and 15.5% of individuals
carry an actionable TPMT low activity genotype (Table 2). Three key
single nucleotide polymorphisms (SNPs), defined as variant alleles
*2,*3A and *3C, lead to an unstable TPMT protein and enhanced pro-
tein degradation.42 They account for >90% of low-activity phenotypes
and have been demonstrated to be highly predictive of the low TPMT
activity phenotype43
To reduce the risk of myelosuppression in mercaptopurine-
treated individuals, clinical guidelines on dose optimisation guided
by the TPMT genotype have been developed by the Clinical
Pharmacogenetics Implementation Consortium (CPIC)25 and Dutch
Pharmacogenetics Working Group (DPWG)44 which are based on
pre-emptive TPMT activity genotyping of the 3 key low-activity
variant alleles (*2,*3A,*3C). It is, however, also important to note
that there are phenotyping tests available for TPMT activity, which
can in theory detect all variants in the TPMT genes (beyond the
3 alleles), and the phenotyping test is widely used. However, clini-
cal phenotyping tests, based on enzyme activity, do have some lim-
itations including not being reliable in patients post blood-
transfusion.45
CPIC guidelines25 recommend that where a starting dose of
75 mg/m2 of mercaptopurine is used for treatment of ALL, a 50%
dose reduction should be considered for individuals who are interme-
diate TPMT metabolisers (carriers of 1 functional and 1 nonfunctional
allele). For poor metabolisers (carriers of 2 nonfunctional alleles) the
recommended dose is 10%.
More recently, genome-wide association studies have identified
variants in NUDT1546 that strongly influence thiopurine intolerance
in ALL patients. NUDT15 encodes a nucleoside diphosphatase that
catalyses the conversion of the cytotoxic thioguanine triphosphate
(TGTP) metabolite to the less toxic thioguanine monophosphate.
TGTP incorporates into DNA forming DNA-TG, the antileukaemic
metabolite.47
Defective NUDT15–mediated catabolism results in elevated
levels of TGTP and subsequently DNA-TG, leading to an increased
risk of myelosuppression. The first NUDT15 SNP associated with
thiopurine toxicity was rs116855232 (c.415C>T), which causes a p.
R139C amino acid substitution resulting in almost complete loss of
enzymatic activity and protein stability in vitro. Carriers of this allele
have elevated DNA-TG levels48 and severe myelosuppression. At
standard maintenance doses of mercaptopurine in ALL, the risk of
myelosuppression in carriers of the p. R139C variants is 14.5-fold
higher than in wild-type individuals.49 Indeed, in other paediatric ALL
cohorts, individuals homozygous for p.R139C tolerated only 8% of
the standard dose, while the figure was 63 and 85% for heterozygous
and wild-type individuals, respectively.46
The p.R139C allele in NUDT15 is by far the most extensively
studied and therefore provides the largest body of evidence for
clinical implementation. However, there are many other variants of
differing frequencies in the NUDT15, for many of which we have
no data on functional activity. To overcome this limitation, a recent
study50 used the technique of saturation mutagenesis to identify
54 residues where variants led to a loss of protein stability, and
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another 17 residues where variants altered NUDT15 activity with-
out affecting protein stability. As more patients have whole
genome sequencing, the data generated by Yang and colleagues50
will become valuable in taking into account all potential variants
that may affect enzyme activity and the need to individualise dose.
However, the complexity of dosing for individual patients should
not be underestimated.
Whilst the influence of inherited TPMT dysfunction on the risk
of thiopurine-induced intolerance is of greater importance in indi-
viduals of European or African ancestry, NUDT15 risk alleles seem
to be more important in those of Asian and Hispanic ethnicity.
Reports of individuals who are intermediate metabolisers for both
TPMT and NUDT15 have been reported (compound intermediate
metabolisers). The 2 genes are independent of each other and the
incidence of carriers of reduced function alleles of both will
depend on population admixture. Therefore, in the individualisation
of 6-mercaptopurine dose in the future, both genes should be eval-
uated irrespective of ethnicity as highlighted by the recent CPIC
guideline.25
2.2 | DPYD and fluoropyrimidines
The fluoropyrimidines, 5-fluorouracil (5-FU) and its oral prodrugs,
capecitabine and tegafur, are indicated for the treatment of colorectal
cancer, breast cancer and other gastrointestinal tract cancers. 5-FU
has a narrow therapeutic index and, although generally tolerated,
10–30% of patients develop severe (grade ≥3) toxicity that can result
in prolonged hospitalisation, or death in 0.5–1% of patients.51–53
Fluoropyrimidine adverse events include neutropenia, diarrhoea, sto-
matitis and hand–foot syndrome.52
The rate-limiting enzyme for 5-FU catabolism is
dihydropyrimidine dehydrogenase (DPYD), encoded by a gene located
on the short arm of chromosome 1, a phase I enzyme that metabolises
80% of 5-FU into noncytotoxic dihydrofluorouracil.54 Assays to
determine DPYD enzymatic activity in peripheral blood mononuclear
cells have been developed. DPYD phenotype can also be determined
by the dihydrouracil/uracil (UH2/U) plasma ratio or the uracil loading
test.15,54 DPYD activity follows a normal distribution55; approximately
3–8% of patients, depending on ethnicity, have partial DPYD
F IGURE 1 Schematic demonstration of variable outcomes of pharmacologically active oncology drugs and prodrugs as determined by
metaboliser phenotype status for key drug metabolising enzymes. ADR = adverse drug reaction
TABLE 2 Studies reporting frequencies of actionable pharmacogenomic variants relevant to oncology drugs
(n)
% population with actionable PGX variant
UGT1A1
(PM) TPMT (PM/IM) DPYD (PM/IM)
G6PD
deficiency
CYP2D6
(PM)
Irinotecan Mercaptopurine
Capecitabine,
fluorouracil Rasburicase Tamoxifen
Chanfreau-Coffinier et al
201937
7 769 359 11.2 5.8 0.9 4.9 -
Bank et al 201938a n/a - 15.5 - - 5.0
Van Driest et al 201439 9589 - 9.1 - -
Reisberg et al 201940 44 000 12.3-13.1 6.4 0.9 - 4.1
Mostaf et al 201841 5408 - - - - 5.7 2.8
PM = poor metaboliser; IM = intermediate metaboliser; UR = ultra-rapid metaboliser.
aEstimates based on percentage actionable phenotypes for count incident prescriptions of specific drug.
6 CARR ET AL.
deficiency,56 which increases 5-FU exposure by 1.5 times relative to
normal DPYD activity.57 Complete DPYD deficiency is rare with a
prevalence of 0.1–0.2%, but can lead to fatal toxicities following
exposure to standard doses of 5-FU.53,56,58 DPYD activity is regulated
by genomic, transcriptional (Sp1 and Sp3 transcription factors) and
post-transcriptional (microRNAs-27a and -27b) factors.59,60 For
instance, hypermethylation of the promoter region of the DPYD gene
has been identified,61 but whether it affects expression and thereby
predisposition to 5-FU toxicity is unclear.62
Genetic variation in the DPYD gene has been extensively investi-
gated. Importantly, a meta-analysis identified 4 DPYD variants to
be strongly associated with 5-FU-associated toxicity: DPYD*2A
(rs3918290, c.1905+1G>A), DPYD*13 (rs55886062, p.I560S,
c.1679T>G), rs67376798 (p.D949V, c.2846A>T), and rs75017182
(HapB3, c.1129–5923C>G).53 In particular, genetic associations have
been found for haematological and gastrointestinal toxicities, but not
with hand–foot syndrome.53 DPYD*2A leads to skipping of exon
14 and a nonfunctional DPYD protein, DPYD*13 and rs67376798 are
missense variants, and rs75017182 (HapB3) in intron 10 introduces a
cryptic splice site.15 Patients with wild-type DPYD are assigned an
activity score (AS) of 2. DPYD*2A and DPYD*13 have the most delete-
rious impact on DPYD activity and so heterozygotes are designated
an AS of 1, and homozygotes/compound heterozygotes an AS of
0. Variants rs75017182 and rs67376798 are thought to moderately
reduce DPYD activity and so heterozygotes are given an AS of 1.5.56
In European populations, rs75017182 (HapB3) is the most common
of these variants with a Minor Allele Frequency (MAF) of 1–4%63;
overall, 7% of Europeans carry at least 1 reduced function DPYD
variant.15 The reduced function missense variant, rs115232898 (p.
Y186C, c.557A>G), occurs in 1–4% of individuals of African ances-
try.64 A recent study in 1254 patients has also suggested DPYD*6
(rs1801160, p.V732I, c.2194G>A), whose MAF is 1–9% depending on
the population, may be associated with 5-FU toxicity,65 although rep-
lication is required. The majority of other recognised deleterious
DPYD variants are rare.15
Fluoropyrimidine guidelines based on the 4 established DPYD var-
iants have been developed by CPIC and DPWG.15,56 These guidelines
and their online updates are broadly similar, recommending a 50%
reduction in starting dose in patients with a DPYD AS of 1–1.5 (het-
erozygous intermediate metabolisers) and avoiding fluoropyrimidine
therapy when possible in those with an AS of 0–0.5 (poor meta-
bolisers). Nevertheless, subtle differences exist between these guide-
lines. For example, the DPWG guideline contains recommendations
for tegafur as well as 5-FU and capecitabine.56
Of interest, a smaller starting dose reduction of 25–50% was pre-
viously recommended for patients with an AS of 1.5 commencing
5-FU/capecitabine. However, the updated 50% dose reduction was
advised following publication of a seminal real-world pharmaco-
genomics implementation study that enrolled 1181 patients from
17 hospitals in the Netherlands and prospectively genotyped them for
DPYD*2A, *13, rs67376798, and rs56038477 (c.1236G>A, which is in
perfect linkage disequilibrium with rs7501718215).66 In this study,
patients received an initial dose reduction of 50% (in DPYD*2A or *13
heterozygotes) or 25% (rs67376798 or rs56038477 heterozygotes),
and were followed up for fluoropyrimidine-related grade ≥3 toxicity
compared to a historical (noninterventional) cohort. The relative risk
for toxicity (carriers vs DPYD wild-type patients) was 1.31 for
genotype-guided dosing in the prospective study but 2.87 in the his-
torical cohort for DPYD*2A carriers, no toxicity (in the 1 carrier) vs
4.30 in *13 carriers, 2.00 vs 3.11 in rs67376798 carriers, and 1.69
compared with 1.72 in rs56038477 carriers.66 Moreover, rs67376798
carriers still had elevated 5-FU exposure compared to wild-type
patients, and there was large variation in DPYD activity in
rs56038477 carriers.66 Thus, the initial dose reduction of 25% for
rs67376798 or rs56038477 carriers was plausibly insufficient and
larger initial reductions (50% starting dose) with individualised dose
titration are now thought preferential.
Despite the strong associations with the above-mentioned DPYD
variants, given the complexity of regulatory processes for the DPYD
gene, and the occurrence of rare variants, genetic variation only
explains up to 30% of the observed early onset 5-FU-associated toxic-
ity.52 DPYD phenotyping is an alternative or complementary strategy,
and has been associated with 5-FU exposure and toxicity, albeit
inconsistently.55,67–69 DPYD phenotyping also has limitations; for
instance, the correlation between hepatic and peripheral blood mono-
nuclear cell DPYD activity is modest (R2 < .6),70 baseline UH2/U ratios
probably reflect unsaturated DPYD and so may not always predict
decreased DPYD activity,68 technical expertise is required, and the
assay is often only available in specialised centres. Furthermore, lack
of assay standardisation and lack of clarity around cut-off levels,
which denote risk, represent further limitations for widespread imple-
mentation of phenotyping assays.
Multiparametric assessments may be valuable here as shown
by a recent nonrandomised multicentre prospective study in
patients with colorectal cancer that used preprescription DPYD
genotyping, UH2/U phenotyping and demographic factors such as
age and sex to determine risk.71 Therapeutic drug monitoring
(TDM, see later) was also used in patients with identified partial
DPYD deficiency to provide further dose optimisation.71 The study
found that the frequency of early 5-FU-based grade 4–5 toxicity
using the multiparametric intervention, compared to standard care,
was significantly reduced from 4.2 to 1.2% (P = .0019).71 More-
over, the intervention was associated with a borderline significant
reduction in the proportion of patients with grade 3–5 toxicity
from 17.6 to 10.8% (P = .0497).71 However, this is a highly com-
plex intervention, and whether it is cost-effective or whether it
can be implemented more widely, is unclear.
2.3 | G6PD and rasburicase
Rasburicase is a recombinant urate oxidase enzyme administered
intravenously and indicated for the prophylaxis and treatment of hyp-
eruricaemia during chemotherapy in patients with haematological
malignancy at risk of tumour lysis syndrome. Rasburicase is con-
traindicated in patients with glucose-6-phosphate dehydrogenase
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(G6PD) deficiency, which is the most common enzyme deficiency in
humans.72,73
G6PD, located on the X chromosome at Xq28 and is ubiqui-
tously expressed.73,74 It converts glucose-6-phosphate to
6-phosphogluconolactone, which is the first step in the pentose
phosphate pathway (PPP), and this step concomitantly reduces nic-
otinamide adenine dinucleotide phosphate (NADP+) to NADPH.73
G6PD is the rate-limiting enzyme of the PPP and, in erythrocytes,
the PPP is the only source of NADPH, which is required to main-
tain cellular levels of reduced glutathione.73–75 Oxidative stress
refers to an increase in reactive oxygen species (ROS) that can lead
to structural cell damage. ROS are chemically reactive species con-
taining oxygen such as superoxide and hydrogen peroxide and,
importantly, reduced glutathione protects cells from oxidative stress
by neutralising ROS.76 However, steep increases in ROS over-
whelm cellular antioxidant defences, including glutathione-mediated
reduction, and erythrocytes are particularly susceptible to oxidative
stress due to their role as oxygen carriers and reliance on G6PD.75
Oxidative stress can be triggered by many factors including infec-
tions, foodstuffs (e.g. fava beans in favism) and specific drugs, for
example, primaquine, nitrofurantoin and rasburicase.77 The oxida-
tion of uric acid to allantoin by rasburicase can lead to oxidative
stress through production of hydrogen peroxide.78
The majority of reported genetic variants in G6PD are missense
variants74; the lack of frameshift variants and large deletions is consis-
tent with the observation that complete loss of G6PD is fatal in
utero.74,79 G6PD variants are classified by the World Health Organisa-
tion into 5 categories80: class I variants are very rare, usually associ-
ated with G6PD activity <10% of normal and occur in symptomatic
patients with chronic nonspherocytic haemolytic anaemia (CNSHA);
classes II and III have G6PD activities of <10% and 10–60%, respec-
tively, but neither are associated with CNSHA and so individuals are
asymptomatic most of the time; class IV variants have normal activity,
and; class V is reserved for variants with increased activity,80 although
only 1 case has been reported.73 Class II and III variants are responsi-
ble for the majority of G6PD deficiency. It is these asymptomatic
patients that are susceptible to oxidative stress following rasburicase
exposure and other triggers.2 The 2 classically recognised variants are
the Mediterranean (G6PDMed, class II) and African American (G6PDA–,
class III) forms.81
Overall, around 400 million people are thought to have G6PD
deficiency, and it is more common in Africa, Southeast Asia, the Medi-
terranean and the Middle East.73 The prevalence of G6PD deficiency
correlates with the worldwide distribution of malaria, leading to the
hypothesis that G6PD deficiency evolved and is maintained due to
selection pressure exerted from Plasmodium parasites, with an advan-
tage being conferred to female heterozygotes.82–85 The main clinical
manifestation of G6PD deficiency is haemolytic anaemia, although
other presentations include neonatal jaundice, methaemoglobinaemia
and CNSHA.86,87 In patients with G6PD deficiency, rasburicase is
associated with haemolytic anaemia and, rarely, concomitant metha-
emoglobinaemia, which is due to oxidation of haemoglobin iron, lead-
ing to methaemoglobin and tissue hypoxia.87,88
The majority of affected individuals are male because G6PD defi-
ciency is X-linked and so only 1 class I, II, or III variant is required
(hemizygosity). However, females can rarely be homozygous or com-
pound heterozygous for G6PD deficiency.89 G6PD genotyping can be
sufficient to establish the diagnosis of G6PD deficiency when specific
variants of known functional consequence are detected.2 However,
the absence of specific variants does not preclude G6PD deficiency
due to the presence of untested or unrecognised variants, and there-
fore G6PD phenotyping is often required to establish G6PD defi-
ciency.2 Moreover, in heterozygous females carrying 1 deleterious
variant, G6PD activity is variable due to X-linked chromosome inacti-
vation (lyonisation) giving rise to mosaicism,90 and so enzyme
phenotyping is needed because G6PD activity cannot be determined
by genotype alone.2 CPIC have produced a guideline to efficiently
combine genotyping with G6PD phenotyping and, in those with
G6PD deficiency in whom rasburicase is contraindicated, an alterna-
tive agent such as allopurinol is recommended.2
In cases of methaemoglobinaemia associated with G6PD defi-
ciency, including after rasburicase, the main medicinal treatment,
methylene blue, is contraindicated due to the risk of exacerbating
oxidative stress, which can make management challenging. In this
setting, the mainstays of treatment are high flow oxygen, ascorbic
acid and blood transfusions.87,88 Ultimately, as our understanding
of the functional impact of G6PD variants increases, alongside
G6PD sequencing or multi-G6PD variant panel testing, the contribu-
tion of genomics to establishing the diagnosis of G6PD deficiency
is anticipated to grow.
2.4 | UGT1A1 and irinotecan
Deficient expression of uridine 50-diphospho-glucuronosyltransferase
1A1 (UGT1A1) is well-described in familial syndromes such as
Crigler–Najjar (Type I) and Gilbert's syndrome.91 In the latter, the
majority of patients have a genetic variation in the promoter region of
the UGT1A1 gene, termed UGT1A1*28, which reduces UGT function
by about 70%. The frequency of the *28 allele is 29–45% in Cauca-
sians, 42–51% in Africans and significantly lower (16%) in Asian
populations.92 Asian patients often have different polymorphisms in
the UGT1A1 gene, such as UGT1A1*6, which also have the same
effect of reducing UGT1 activity.
Irinotecan is used in the treatment of colorectal and small cell
lung cancer. It is a prodrug that is phase I metabolised to its pharma-
cologically active SN-38 form by carboxylesterases and subsequently
glucuronidated to a hydrophilic conjugate by UGT1A1. A common
variable nucleotide tandem repeat polymorphism in the UGT1A1 gene
promoter, known as the *28 allele, leads to reduced transcription of
UGT1A1 and lower hepatic enzyme expression. UGT1A1*28 carriage
is associated with impaired glucuronidation of irinotecan and elevated
circulating SN-38 levels32 .
Significant evidence exists demonstrating that individuals
homozygous for UGT1A1*28 are predisposed to serious adverse drug
reactions (ADRs; neutropenia and diarrhoea) with irinotecan.93 A
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meta-analysis of studies utilising UGT1A1*28 genotyping in
irinotecan-treated Caucasian patients94 reported an increased risk of
irinotecan-induced adverse events in *28/*28 individuals compared to
*1*1 with neutropenia with an odds ratio (OR) = 4.79 (95% confidence
interval [CI] 3.28–7.01; n = 1095) and diarrhoea, OR = 1.85 (95% CI
1.24–2.72; n = 1122). Because of this, the Food and Drug Administra-
tion amended the irinotecan label in 2004 to advocate dose reduction
in *28/*28 carriers, and subsequently revised it to recommend *28
testing prior to irinotecan therapy in 2010. An analysis of the Japa-
nese Biobank showed that UGT1A1*6/*6 genotype increased the risk
of irinotecan-induced ADRs (OR = 6.59, 95% CI 2.33–18.6).95
As would be expected, dose is also important in predisposing
to the serious adverse reactions associated with irinotecan. In a
meta-analysis of 821 patients, the risk of toxicity was higher
among patients carrying at least 1 UGT1A1*28 allele when com-
pared with UGT1A1*1/*1 patients given medium and high doses of
irinotecan, but not at lower doses (100–125 mg/m2), which are in
the commonly used therapeutic range.96 Consistent with this, the
French National Network of Pharmacogenetics has proposed no
dose reduction in carriers of the UGT1A1*28 allele when the dose
given is <180 mg/m2/wk, but with a dose reduction of 25–30% in
*28/*28 patients when the dose is 180–230 mg/m2 2–3 weekly
and contraindicating use when the dose is ≥240 mg/m2 2–3
weekly.97 By contrast, the Dutch Pharmacogenetics Working Group
guidelines for UGT1A1 and irinotecan98 recommend starting with
70% of the standard initial dose in *28/*28 patients irrespective
of dose, but with no dose change in heterozygote patients, and
with a dose increase if tolerated, guided by neutrophil count
monitoring.
Given that irinotecan is currently largely used in combination
therapies and at lower doses, the use of UGT1A1 genotyping is not
common.
2.5 | CYPD6 and tamoxifen
Cytochrome P450 2D6 (CYP2D6) is a key phase I drug metabolising
enzyme, thought to metabolise 25% of all licensed drugs.99,100
CYP2D6 is a highly polymorphic gene and 5-10% of the population
carry 2 nonfunctional alleles, and are referred to as CYP2D6 poor
metaboliser (PM) while 1–30% of the population, depending on eth-
nicity, carry duplications of functional alleles and are referred to as
ultrarapid metabolisers.
Tamoxifen is a selective oestrogen receptor modulator com-
monly used to both treat and prevent breast cancer. It is
metabolised to its active form endoxifen by CYP2D6. For ultra-
rapid and normal metabolisers, therapeutic levels of endoxifen are
typically achieved and these individuals are recommended to com-
mence standard of care dosing (20 mg/d) avoiding concomitant
administration of other drugs known to be moderate/strong
CYP2D6 inhibitors.101
Individuals who are CYP2D6 PMs typically have lower circulating
levels of endoxifen than those who are extensive metabolisers,102 and
have been shown to have reduced efficacy and therefore a worse
prognosis.103 As such, guidelines have been developed that recom-
mend that PMs receive an alternative therapy such as aromatase
inhibitors or if contraindicated, an increase in tamoxifen dose to
40 mg/d should be considered.101 There is, however, controversy due
to the inconsistent evidence as to whether pre-emptive CYP2D6
genotyping actually improves clinical outcomes with some large trials
reporting conflicting results.6
Controversy also exists as to what therapeutic adjustment should
be made in individuals who are normal or intermediate metabolisers
since alleles such as CYP2D6*10, infer a nonfunctional enzyme rather
than reduced function. As such the enzymatic activity score for IMs
can vary substantially and subsequently so can the systemic endoxifen
levels. Indeed, it has been suggested that therapeutic drug monitoring
of endoxifen levels may represent a more accurate means by which to
phenotype metaboliser status in order to individualise tamoxifen
therapy.104
To attempt to address the controversies, the international tamoxi-
fen pharmacogenetics consortium (ITPC)105 undertook a meta-
analysis of 4973 patients from 12 international sites. Using strict eligi-
bility criteria (postmenopausal women with oestrogen receptor posi-
tive breast cancer receiving tamoxifen for 5 years), an association
between CYP2D6 PM status and worse invasive disease-free survival
was determined (hazard ratio = 1.25 (1.06–1.47); P = .009). However,
the authors did point out that inclusion criteria were not defined a
priori and so further prospective studies are needed to establish the
utility of CYP2D6 genotyping.
Although much work to standardise patient inclusion criteria, as
well as disease and outcome phenotypes, has been undertaken in the
intervening years, the clinical utility and benefit of CYP2D6
genotyping prior to tamoxifen therapy remains contentious.
3 | ASSOCIATIONS WITH A LOWER LEVEL
OF EVIDENCE
The drug–gene associations described above are considered to
have a comparatively high level of evidence and clinical
pharmacogenomic guidelines have been developed for each from
at least 1 of the pharmacogenomic guideline writing consortia. In
general, it is the body of supportive evidence rather than a pivotal
trial that forms the basis of these guidelines in oncology. Never-
theless, several other genes have been associated with adverse
reactions to specific oncology drugs, although the evidence is
either currently restricted to 1 or a few studies, or is presently
inconsistent. Many of these are highlighted in Table 1. Given the
lack of space, we have not covered every association between
pharmacogenomic variants and drug response, usually toxicity,
associated with the individual drugs—readers are referred to the
cited references for further detail. Some of these associations are
described below to highlight the complexities of identifying clini-
cally relevant associations, and we also hope that this may stimu-
late further research in these areas.
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3.1 | ABCB1 and chemotherapy toxicity
The adenosine triphosphate (ATP)-binding cassette (ABC) subfamily
B (MDR/TAP) member 1 (ABCB1) gene encodes P-glycoprotein
1 (P-gp), which is a widely expressed membrane-associated ATP-
dependent xenobiotic efflux pump with broad substrate specificity.
Examples of P-gp oncology drug substrates include doxorubicin,
docetaxel, paclitaxel and vincristine; doxorubicin and vincristine
also induce P-gp.106 Multidrug resistance (MDR) is a major cause
of chemotherapy failure in metastatic cancer. It is a multifactorial
and incompletely understood phenomenon, but basal and drug-
induced P-gp overexpression in cancer cells has been associated
with treatment failure in several cancer types,107 highlighting
the importance of P-gp to drug response. ABCB1 is highly polymor-
phic, but studies to date have tended to focus on 1 or more of
3 common ABCB1 variants and/or their haplotypes: c.1236C>T
(rs1128503, a synonymous variant), c.2677G>T/A (rs2032582, a
missense variant) and c.3435C>T (rs1045642, a synonymous
variant). In addition, ABCB1 c.1199G>A (rs2229109, a missense
variant) has been shown to increase in vitro efflux transport of
the tyrosine kinase inhibitors dasatinib, imatinib, nilotinib,108
although its effect on predisposition to tyrosine kinase inhibitor-
induced ADRs (particularly gastrointestinal toxicity) has yet to be
demonstrated.
Genetic variation in ABCB1 has been variably associated with
cancer survival109 and ADRs including anthracycline-induced
cardiotoxicity,26 paclitaxel-medicated peripheral neuropathy and
neutropenia,110 and vincristine neurotoxicity111 in some, but not all
studies.109,112,113 Some of this variability may be attributable to
small sample sizes and interethnic differences.109 However, overall,
the evidence is too inconsistent at present to support ABCB1
genotyping.
3.2 | CYP2B6 and cyclophosphamide
Cyclophosphamide is an alkylating agent indicated for a range of
haematological and solid organ cancers including lymphoma and
breast cancer, respectively. It is also used as an immunosuppressive
in specific autoimmune diseases and bone marrow transplantation. It
is a prodrug that is biotransformed to the intermediate metabolite,
4-hydroxy-cyclophosphamide, by hepatic CYP2B6 amongst other
CYPs, which undergoes further nonenzymatic conversion to the ther-
apeutically active metabolite, phosphoramide mustard.114 In a genetic
analysis of patients with chronic lymphocytic leukaemia within a
randomised controlled trial, carrying the reduced function CYP2B6*6
allele was associated with a lower likelihood of achieving a complete
response and fewer adverse events in patients on fludarabine plus
cyclophosphamide, but not in patients that received fludarabine or
chlorambucil alone.115 Notwithstanding the reduced adverse events,
the inferior efficacy signal, if confirmed, suggests cyclophosphamide
may be unsuitable in patients carrying CYP2B6*6 and alternative che-
motherapy advisable.
3.3 | CYP3A7 and CYP3A-metabolised
chemotherapeutics
The human CYP3A subfamily consists of CYP3A4, 3A5, 3A7 and
3A43. CYP3A7 is the main foetal hepatic CYP.116 However, after
birth, CYP3A7 expression is downregulated whilst CYP3A4 expres-
sion increases. Thus, CYP3A4 is the major adult CYP3A isoform,
with adult levels reached around age 1 year.117 Nevertheless,
CYP3A7 mRNA expression varies extensively and in 10% of adult
livers, CYP3A7 is detectable and contributes 9–36% of total
CYP3A protein.118 The allele, CYP3A7*1C, results from 60 bp of
its promoter region being replaced by the corresponding region of
the CYP3A4 adult promoter, and is thus associated with increased
hepatic and intestinal CYP3A7 expression.119,120 Interestingly, a
putative interaction of borderline significance (Pinteraction = .06)
has been found between carrying CYP3A7*1C, treatment with a
CYP3A-substrate chemotherapeutic, and increased mortality in
breast or lung cancer and disease progression in chronic lympho-
cytic leukaemia.121 These findings are of particular interest because
CYP3A metabolises approximately 30% of clinically used drugs122
yet, except for CYP3A5*3 and potentially CYP3A4*22 with
tacrolimus,123 pharmacogenomic associations within the CYP3A
locus have proved elusive. This may be because CYP3A4 activity is
modulated by multiple interacting genes and inhibition/induction
via myriad of environmental factors.124
3.4 | SLCO1B1 and methotrexate
Methotrexate is an antimetabolite used as an anticancer drug, notably
in paediatric ALL, and as an immunosuppressant. The solute carrier
organic anion transporter family member 1B1 (SLCO1B1) gene
encodes the hepatic xenobiotic influx transporter, organic anion trans-
porter polypeptide 1B1 (OATP1B1). Candidate gene studies125–127
and a GWAS27 in paediatric ALL have identified genetic variants in
SLCO1B1 that are associated with reduced methotrexate clearance.
The most important variant is likely to be the reduced function
SLCO1B1 SNP, rs4149056 (c.521T>C, p.V174A), as several of the
other identified SLCO1B1 variants (e.g. rs4149081, rs11045879,
rs11045821125,126) are in linkage disequilibrium with rs4149056.27 It
is notable that the SLCO1B1 rs4149056 minor allele is also associated
with increased exposure to most statins, and is considered an action-
able pharmacogenomic variant for simvastatin myotoxicity.128 It may
also be associated with reduced risk of chemotherapy-induced
amenorrhoea.129
Interestingly, a SNP–SNP interaction has been observed with
methotrexate clearance between rs4149056 and gain-of-function
rs2306283 (c.388A>G, p.N130D), which together define the most
common SLCO1B1 haplotypes (*1a, *1b, *5, *15).27 Within each
rs4149056 genotype group, the rs2306283 ancestral A allele is asso-
ciated with even lower methotrexate clearance.27 Importantly, metho-
trexate plasma concentrations have been correlated with increased
global methotrexate toxicity.126 Nevertheless, in adult haematological
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malignancies, rs4149056 and rs2306283, have not been associated
with methotrexate exposure,28,130 and variably associated with
toxicity.28,130
Intriguingly, 70–90% of methotrexate is eliminated in urine, yet
OATP1B1 expression is limited to hepatocytes. SLCO1B1 rs4149056
and rs2306283 variants significantly alter the abundance of specific
metabolites in urine. Moreover, these metabolites are substrates for
renal organic anion transporters (OATs) such as methotrexate, and
half were associated with methotrexate toxicity.28 This suggests that
complex transporter–transporter interactions mediated by endoge-
nous substrates may have a role in methotrexate clearance and
toxicity.
4 | PHARMACOGENOMICS
IMPLEMENTATION IN ONCOLOGY AND
BROADER CLINICAL PRACTICE
Over the past decade, there has been slow but growing implementa-
tion of pharmacogenomics into real world practice. Many initiatives
have implemented reactive single gene testing in individual healthcare
institutions. For example, routine DPYD genotyping has been demon-
strated to be acceptable and feasible, and to reduce the risk of severe
fluoropyrimidine toxicity in implementation initiatives.57,66,131 More-
over, single gene DPYD genotyping has been reported to be highly
likely cost saving.132
Nevertheless, 99% of the population are estimated to
carry at least 1 actionable pharmacogenomic variant within
13 pharmacogenes.37 This observation has contributed to several
initiatives utilising pharmacogene panel testing. For example,
the European Ubiquitous Pharmacogenomics consortium has
implemented genotyping 44 variants in 12 genes (including
CYP2D6, DPYD, TPMT and UGT1A1) in a single test for patients
starting 1 of 42 drugs and are recruited into the PREPARE
implementation research study (ClinicalTrials.gov Identifier:
NCT03093818).133 Whilst patient recruitment and genotyping in
PREPARE are reactive to the index drug prescription, the other
results are available pre-emptively for future prescribing. Several
other initiatives implementing pharmacogene testing have been set
up, such as eMERGE,134 IGNITE135 PG4KDS136 and ACCOuNT.137
This pre-emptive approach is highly relevant in oncology because
patients with cancer may have or develop indications for other
actionable drug gene pairs: for example, nausea on chemotherapy
(CYP2D6-ondansetron), pain (CYP2D6-codeine/tramadol), anxiety
and depression (CYP2D6 or CYP2C19-selective serotonin reuptake
inhibitors), and concurrent or future cardiovascular risk prevention
(SLCO1B1-simvastatin).
Beyond variant genotyping, NGS of specific pharmacogenes
represents another strategy with the potential advantage of
enabling patient pharmacogenomic results to keep pace with
research progress in ascribing function to pharmacogene variants
of uncertain significance, without the need for re-testing. More-
over, at least 14 countries have government-funded national
genomic medicine initiatives138 and so a rapidly increasing number
of patients will undergo whole exome and whole genome sequenc-
ing over the coming decade, accelerating the availability of
pharmacogenomic results. For example, the UK 100 000 Genomes
Project has a pilot programme to extract actionable DPYD variants
from whole genome sequencing data in participants with cancer
and make them available to clinicians via regional genomic medi-
cine centres.139
Nevertheless, pharmacogenomic implementation remains ardu-
ous and complex with a need for multidisciplinary team
working and stakeholder engagement to surmount the multiple
barriers that include evidential, healthcare practitioner knowledge,
financial and logistical.140 However, the experiences learned from
early adopter sites will help facilitate broader implementation.141
One specific challenge is the inherent complexity of particular
pharmacogenes, and CYP2D6 in particular. CYP2D6 can be affected
by structural variations including gene deletion, multiplication, and
tandem rearrangements or hybrid gene conversions with its
upstream pseudogene, CYP2D7.142 These structural variants impede
accurate CYP2D6 genotype-to-phenotype translation by conven-
tional methods and standard short read sequencing.143 However,
long-read sequencing has been demonstrated to accurately geno-
type and phase CYP2D6 and so offers a promising way
forward.142,144
A second major challenge is the introduction of clinical deci-
sion support (CDS) systems, which are essential to support pre-
emptive pharmacogenomic testing.141 CDS can be passive, relying
on the user to seek out the recommendations, or actively interrupt
healthcare practitioners with automatic alerts. CDS can also either
be integrated into existing information and communications tech-
nology (ICT) infrastructure, such as electronic healthcare records, or
provided in separate programs such as web services, and patient-
held healthcare safety-code cards or mobile applications.145 An ideal
system provides up-to-date recommendations when prescribing
(or dispensing) a new drug to maximise uptake of recommenda-
tions, is user-friendly, a gateway to resources for impromptu user-
directed learning, and recalls previous test results automatically
when prescribing in future to avoid genetic re-testing. Thus active,
interruptive CDS systems appears advantageous, providing alerts
are judicious to mitigate alert fatigue. However, the heterogeneity
of healthcare ICT systems and financial resources available for inte-
gration represent significant hurdles to broader adoption. It is
expected that local solutions will be required, and hybrid models
that variably implement through both central ICT infrastructure and
patient-held devices might expedite implementation by decreasing
reliance on any 1 system.
Lastly, the availability of consensus guidelines is paramount for
successful implementation. Whilst CPIC and DPWG guidelines are an
excellent resource and share a high degree of congruence, some dif-
ferences exist between their recommendations.146 Furthermore, exis-
ting guidelines offer little guidance on when to order genetic tests,
may need translating, and potentially adapting to best fit a regi-
onal/national healthcare setting.
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5 | MOVING BEYOND COMMON VARIANT
AND SINGLE GENE PHARMACOGENOMICS
To date, the majority of ADR pharmacogenomic associations in oncol-
ogy and other specialties relate to select, predominantly common, var-
iants in a single germline gene. However, advances in technologies,
sample sizes, and data processing mean that pharmacogenomics will
be likely to evolve to encompass rare genomic variation, polygenic risk
scores and pharmacomicrobiomics, and complement TDM.
5.1 | Rare variation
The first observations in the 20th century that ADRs could have a
genetic basis were arguably in anaesthetics with malignant hyperther-
mia147 and prolonged apnoea148 following exposure to volatile anaes-
thetics or succinylcholine, respectively. These ADRs are rare and
potentially life threatening. Subsequently, rare gain-of-function muta-
tions in ryanodine receptor 1 (RYR1) or, to a lesser extent, the calcium
voltage-gated channel subunit α1 S (CACNA1S) have been identified
in individuals affected by malignant hyperthermia.149,150 Pseudocho-
linesterase deficiency increases the risk of clinically relevant pro-
longed apnoea and can be acquired, or inherited in individuals that
receive 2 reduced function butyrylcholinesterase (BChE) alleles.151
Thus, these early examples highlight the importance of rare
variants/genotypes in drug response.
Rare variants are generally defined as variants with a minor allele
frequency of <1%.152 Recent genetic epidemiological research has
demonstrated that 93% of single nucleotide variants are rare in
146 pharmacogenes that influence drug pharmacokinetics.153 More-
over, individuals of European and African ancestry harbour, on aver-
age, 101 and 121 single nucleotide variants within these
146 pharmacogenes, respectively.153 Importantly, the contribution of
rare and common variation to the putative function of individual
pharmacogenes varies substantially between genes and overall, up to
30-40% of genetic-mediated functional variation in pharmacogenes
might be attributable to rare variants.153,154
In oncology, germline rare variants in SLCO1B1 identified by deep
resequencing have been associated with methotrexate clearance in
paediatric ALL, in addition to common SLCO1B1 variation.127 In total,
a third of observed variability in methotrexate clearance in these ALL
patients could be explained: 22.7% by clinical covariates and 10.7%
by SLCO1B1 genotypes, of which about a fifth was attributable to rare
variants.127
Deleterious germline rare variants in CYP3A4 have also been
associated with increased frequency and severity of paclitaxel-
induced peripheral neuropathy and increased treatment modifications
due to peripheral neuropathy.11 Specifically, whole-exome sequencing
identified a CYP3A4*20 (premature stop codon) carrier and a novel
CYP3A4*25 (deleterious missense variant) carrier from 8 patients with
severe neuropathy; subsequent CYP3A4 variant screening by denatur-
ing high-performance liquid chromatography in 228 paclitaxel-
exposed patients found 3 more CYP3A4*20 carriers and a carrier of
each of CYP3A4*8 and CYP3A4*27 (deleterious missense variants).11
Similarly, exome sequencing a patient who had suffered severe (grade
4) toxicity after the first cycle of 5-FU based adjuvant chemotherapy
for colorectal cancer identified a novel splicing variant (c.321+2T>C)
in DPYD.155 As the patient was heterozygous, her 5-FU chemotherapy
was restarted at a lower dose (30%) with subsequent titration, and
she completed the whole chemotherapy course.155
As NGS is applied to larger and more ethnically diverse cohorts,
the panoply of identified rare variants will continue to grow. However,
functional characterisation of these variants remains challenging, with
most being classified as variants of uncertain significance. Most com-
putational tools for predicting the function of exonic variants were
calibrated on variants associated with disease and rely on evolutionary
conservatism, yet many pharmacogenes are poorly conserved.156
Thus, a new optimised computational framework that integrates sev-
eral algorithms has recently been developed and validated using
experimental activity data from 337 variants in 43 pharmacogenes,
and was shown to significantly outperform existing bioinformatics
prediction algorithms.156 Furthermore, state-of-the-art saturation
mutagenesis and massively parallel functional assays has recently been
applied to NUDT15, demonstrating the potential of high-throughput
functional screening,157 as outlined above. Briefly, a mutagenesis
library of 3077 missense variants was constructed, representing
99.3% of all possible amino acid substitutions across the 163 residues
of NUDT15. The in vitro functional effects of each variant on protein
abundance and thiopurine toxicity were separately tested; overall, of
the 2844 variants successfully analysed in both assays, 1103 variants
were identified as damaging. In 2398 patients treated with
thiopurines, 10 NUDT15 missense variants were identified, of which
6 were novel and rare. Importantly, the in vitro functional activity of
these variants accurately predicted which alleles were associated with
thiopurine toxicity with 100% sensitivity and specificity, in contrast to
the relatively poor performance of conventional bioinformatic
algorithms.157
These studies collectively demonstrate the abundance of rare var-
iation in pharmacogenes, the enrichment of rare deleterious variants
in patients with extreme phenotypes, and the novel approaches being
developed to predict and empirically assess the functional effects of
rare variants on gene products. It will be crucial to utilise the large
scale genomic-medicine programmes active throughout the world,138
with many incorporating NGS and patients with cancer, coupled to
high throughput functional testing, to advance our understanding of
rare variant pharmacogenomics in oncology.
5.2 | Polygenic risk scores
The identification of increasing numbers of variants of low effect
size with common conditions has paved the way for polygenic risk
scores (PRS) that combine variants, typically weighted on their
effect size, to improve discriminative capability. A recent PRS in
coronary artery disease, for example, consisted of 1.7 million vari-
ants and had higher concordance between model-based risk
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estimates and observed incident events than any of 6 traditional
cardiovascular risk factors.158 In oncology, PRS have been recently
developed for at least 12 different cancer traits including breast,
prostate and skin, with the number of SNPs ranging from 5 to
313.159,160 Such complex disease PRS appear to predict disease
risk particularly accurately at the extremes of the risk
distribution.159
Hitherto, there has been little investigation into
pharmacogenomic PRS. This is likely to be due in part to the effect
sizes for many single gene–drug associations being large compared
to those of complex disorders, plausibly due to limited evolutionary
selection pressure on these variants.140 Thus, single gene/variant
associations can be clinically actionable by themselves and directly
adopted into guidelines.146 It is also notable that cohort sizes for
studying common disease genetics have rapidly grown, reflecting
the recognised underlying genetic complexity of these diseases.
Whilst such cohorts are well suited to development of disease
PRS, the quality of drug utilisation and drug response phenotypic
data in these cohorts is heterogeneous and can make
pharmacogenomic investigations particularly challenging. The recent
introduction of primary care data including medications into UK
Biobank should help address this. Nevertheless, in cardiology, for
example, a PRS of 61 common variants was a significant predictor
of drug-induced torsade de pointes.161 Moreover, in patients with
advanced breast cancer in a clinical trial of paclitaxel, nab-paclitaxel
and ixabepilone (microtubule targeting agents), a set of 13 variants
increased the area under the receiver operating curve for
progression-free survival from 0.64 to 0.81.162 It has also been
shown that the cumulative incidence of venous thromboembolism
in patients with breast cancer is independently increased by che-
motherapy and a PRS consisting of 9 genetic SNPs. Importantly,
the influence of chemotherapy and high PRS (>95th percentile)
were additive, and being in the older age stratum added further
venous thromboembolism risk.163 These examples demonstrate the
potential of PRS to predict ADRs and drug effectiveness, and so
their prominence in pharmacogenomics is likely to grow.
5.3 | Pharmacomicrobiomics
Commensal microorganisms (the microbiota) have evolved into a
diverse array of specialised lineages that form microbial communities
on all the surface barriers of our bodies.164 The microbiota and its
larger host represent a meta-organism, where crosstalk between the
host's immune system and the microbiota have co-evolved multiple
mechanisms for maintaining homeostasis.165 The gut microbiome of
the large intestine is particularly abundant and diverse. Importantly,
there is growing recognition that gut microbiota can influence the
efficacy and toxicity of drugs through several mechanisms including
metabolism, immunomodulation, translocation, and reduction in
microbiome diversity.165
Irinotecan can cause both acute and delayed (over 24 hours
after administration) toxicity. Whilst acute diarrhoea is attributable
to cholinergic stimulation, the gut microbiome is implicated in
delayed-type irinotecan diarrhoea.166 The major route of irinotecan
excretion is via faeces. Interestingly, UGT1A1-glucuronidated SN-
38 (SN-38G) can be deconjugated by secreted bacterial β-
glucuronidase back to active SN-38 in the gut lumen. Free
intestinal SN-38, derived from either intestinal deconjugation or
direct biliary elimination of SN-38, is thought responsible for
irinotecan delayed diarrhoea.166 Bacterial β-glucuronidase inhibitors
have been developed and shown to protect mice from irinotecan-
induced colonic damage and diarrhoea without adversely affecting
plasma SN-38 levels.167,168 Furthermore, 2 distinct faecal meta-
boliser phenotypes (high vs low) have been identified from healthy
volunteer stool samples, based on ex vivo incubation with SN-
38G.169 Subsequent clinical studies that correlate cancer patient
faecal β-glucuronidase activity with irinotecan toxicity endpoints
are now required.
The gut microbiome has also been associated in preclinical
models with decreased methotrexate toxicity and increased
oxaliplatin-induced peripheral neuropathy. Like irinotecan, metho-
trexate can cause severe gastrointestinal toxicity. Interestingly,
genetic knockout of toll-like receptor 2, or microbiota depletion
with antibiotics, resulted in more severe methotrexate-mediated
intestinal mucositis in mice.170 Toll-like receptor 2 stimulation
in myeloid cells increased P-gp synthesis and drug-efflux
activity,170 and may reduce gastrointestinal toxicity by decreasing
intracellular methotrexate accumulation. Germ-free mice, and tem-
porary eradication of gut microbiota using antibiotics has also been
associated in mice with decreased oxaliplatin-induced hyperalgesic
pain.171
Immunotherapy using monoclonal antibody immune checkpoint
inhibitors (ICIs) that overcome cancer-mediated immune suppression
represent a pivotal breakthrough in cancer therapeutics. However,
not all patients benefit from ICIs and some experience severe
immune-related adverse events.172 Thus, there is considerable inter-
est in biomarker identification for treatment stratification. The gut
microbiome has been implicated in both ICI efficacy and toxicity.173
For example, in 26 patients with metastatic melanoma receiving
ipilimumab, which targets cytotoxic T-lymphocyte–associated
antigen 4, baseline microbiota enrichment in Faecalibacterium and
other Firmicutes was associated with both longer survival and more
frequent ipilimumab-induced colitis, compared to microbiota driven
by Bacteroides.174 A recent seminal case series of ICI-colitis suc-
cessfully treated with faecal microbiota transplantation provides
preliminary evidence that modulating the gut microbiome may over-
come ICI-colitis.175
Overall, these examples highlight the growing need to character-
ise the microbiome of patients receiving chemotherapeutics to iden-
tify novel factors predictive of toxicity and gain greater mechanistic
insight. These approaches should aid treatment stratification and/or
development of novel interventions to mitigate chemotherapeutic
toxicity. Given the significant gastrointestinal safety profile of
many cancer drugs, this currently represents an area of significant
unmet need.
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5.4 | TDM
The exposure and response to most drugs is influenced by multiple
factors. Clearly, the importance of genomics to drug efficacy and tox-
icity varies between drugs and outcomes, and so application of phar-
macogenomics (or pharmacomicrobiomics) will not be feasible for
several drugs. TDM is another strategy for medicines optimisation.
TDM could complement preprescription pharmacogenomics recom-
mendations through early dose refinement, or be used on its own
where pharmacogenomic recommendations for a drug do not exist.
Drugs with extensive interindividual variation, narrow therapeutic
window, severe ADRs, and where the majority of pharmacological
activity is attributable to 1 analyte, are particularly well suited for
therapeutic monitoring. In particular, CYP3A metabolic function varies
30–40-fold,176 yet, as mentioned above, the major adult isoform,
CYP3A4, is generally regarded to lack common genetic variants of
large effect size, in contrast to other drug-metabolising CYPs such as
CYP2D6, CYP2C9 and CYP2C19. Interestingly, the oral angiogenesis
inhibitor, pazopanib, is partially eliminated by metabolism mainly by
CYP3A4177; determination of pazopanib plasma concentrations in
patients with renal cell carcinoma may help optimise systemic expo-
sure for efficacy whilst decreasing the risk of specific ADRs including
diarrhoea, hand–foot syndrome and stomatitis.178 Other examples
where therapeutic drug monitoring can improve the benefit-risk pro-
file include the CYP3A4 substrate, imatinib,179,180 high-dose metho-
trexate181,182 and 5-FU therapy.183,184 There are challenges for TDM,
however, which include its lack of broad availability due to the need
for specialised assays and equipment, and incompletely defined
exposure–response relationships.
6 | CONCLUSION
Pharmacogenomic germline variation is common and can influence
the response to anticancer drugs, both efficacy and safety. In par-
ticular, there are a number of pharmacogenomic variants that
which have been associated with an increased risk of serious
ADRs. Although the number of pharmacogenetic variants that have
been implemented into clinical practice is small, as genomics data
become more widely available, there will be an increasing need to
consider pharmacogenetic variants, both common and rare, and
whether they should be utilised to improve prescribing, both dose
and choice of drug, in cancer treatment. Clearly this cannot be
used in isolation, and must be used in combination with somatic
genotypes, and clinical factors (such as age, renal function, hepatic
function and concomitant drugs). Furthermore, additional technolo-
gies such as microbiomics and therapeutic drug monitoring, may
also be of use with certain drugs. This inevitably makes the treat-
ment of patients with cancers more complex—arguably this may
not be a problem in oncology because most oncologists are already
highly practiced in complex therapeutics. Nevertheless, com-
puterised decision support systems will probably be needed in the
future to reduce the problem of prescribing errors, and to aid the
implementation of pharmacogenomics into clinical practice. It is
important to point out that while oncology is regarded as the
poster child for precision medicine, this has largely been based on
improving efficacy. True precision medicine in oncology should
address both efficacy and safety in the same patient.
Nomenclature of Targets and Ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY.
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